BOT - Anything but charting, page-8645

Exactly, as NewbeHK said ..it takes years to be in situation like BOT now...

- years of developments and approval
- Over 100mln was spent on Sofdra development..
- very rare when you have same drug already being sold overseas so successfully..

We all can assume what sales numbers can be ..but we have some indications...

1. Japan sales and growth trajectory 2. JAPAN 70% OF NEW customers in the mix 3. US over 50% dermatologist said Sofdra will be first choice of prescription 4. In US can keep customer data for 12 months and send re-fills 5. How many re- fills??? 6. Insurance is covered 6. Telemedecine channel established to target 6.3mln prospective patients 7. Sales force and social media plan in place to target 3.7mln patients already known to dermatologists ..


We waited for years....literally for years..and now all is loaded > this can really be something special even if we get to 2% of the market in 12-18Months...

ar 2% of the market is easy usd 2.5 per share